AACR 2019: Highlights on Acute Myeloid Leukaemia

AACR 2019

Speaker: Alexander Perl

Reporting from AACR 2019 in Atlanta, A. Perl gives an overview of the practice changing results from a Phase III study on kinase inhibitor, gilteritinib in refractory AML with FLT3 mutation.

Abstract: CT184 - Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial